WO2008078588A1 - Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation - Google Patents

Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation Download PDF

Info

Publication number
WO2008078588A1
WO2008078588A1 PCT/JP2007/074212 JP2007074212W WO2008078588A1 WO 2008078588 A1 WO2008078588 A1 WO 2008078588A1 JP 2007074212 W JP2007074212 W JP 2007074212W WO 2008078588 A1 WO2008078588 A1 WO 2008078588A1
Authority
WO
WIPO (PCT)
Prior art keywords
articular cartilage
pharmaceutical agent
prevention
treatment
apoptosis
Prior art date
Application number
PCT/JP2007/074212
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshinori Asou
Eisuke Tsuda
Original Assignee
National University Corporation Tokyo Medical And Dental University
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Tokyo Medical And Dental University, Daiichi Sankyo Company, Limited filed Critical National University Corporation Tokyo Medical And Dental University
Priority to JP2008551037A priority Critical patent/JPWO2008078588A1/en
Publication of WO2008078588A1 publication Critical patent/WO2008078588A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are a pharmaceutical agent and a method for effectively preventing the apoptosis of an articular cartilage in osteoarthritis or the like. Specifically disclosed are: a pharmaceutical agent for preventing the apoptosis of an articular cartilage, which comprises an osteoclastogenesis inhibitory factor as an active ingredient; and a method for preventing the apoptosis of an articular cartilage, which comprises administering an osteoclastogenesis inhibitory factor to a subject.
PCT/JP2007/074212 2006-12-25 2007-12-17 Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation WO2008078588A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551037A JPWO2008078588A1 (en) 2006-12-25 2007-12-17 Medicament and method for treating or preventing articular cartilage degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-347095 2006-12-25
JP2006347095 2006-12-25

Publications (1)

Publication Number Publication Date
WO2008078588A1 true WO2008078588A1 (en) 2008-07-03

Family

ID=39562381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074212 WO2008078588A1 (en) 2006-12-25 2007-12-17 Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation

Country Status (3)

Country Link
JP (1) JPWO2008078588A1 (en)
TW (1) TW200833841A (en)
WO (1) WO2008078588A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520011A (en) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Anti-RANK ligand monoclonal antibodies useful in treating RANK ligand mediated disorders
JP2004537980A (en) * 2001-04-03 2004-12-24 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Inhibitor of osteoclast differentiation in milk
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520011A (en) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Anti-RANK ligand monoclonal antibodies useful in treating RANK ligand mediated disorders
JP2004537980A (en) * 2001-04-03 2004-12-24 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Inhibitor of osteoclast differentiation in milk
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHAMOUX E. ET AL.: "OPG DECREASES HUMAN OSTEOCLAST APOPTOSIS BY BLOCKING TRAIL PATHWAY", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 21, no. SUPPL. 1, September 2006 (2006-09-01), pages S260 - S261 *
DATABASE WPIDS [online] 2005, accession no. STN Database accession no. (2005_746411) *
EMERY J.G. ET AL.: "OSTEOPROTEGERIN IS A RECEPTOR FOR THE CYTOTOXIC LIGAND TRAIL", J. BIOL. CHEM., vol. 273, no. 23, 1998, pages 14363 - 14367 *
KONG Y.Y. ET AL.: "ACTIVATED T CELLS REGULATE BONE LOSS AND JOINT DESTRUCTION IN ADJUVANT ARTHRITIS THROUGH OSTEOPROTEGERIN LIGAND", NATURE, vol. 402, no. 6759, 1999, pages 304 - 309, XP002987950, DOI: doi:10.1038/46303 *
LEE S.W. ET AL.: "TRAIL INDUCES APOPTOSIS CHONDROCYTES AND INFLUENCES THE PATHOGENESIS OF EXPERIMENTALLY INDUCED RAT OSTEOARTHRITIS", ARTHRITIS RHEUM., vol. 50, no. 2, 2004, pages 534 - 542 *
PETTERSEN I. ET AL.: "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND INDUCES APOPTOSIS IN HUMAN ARTICULAR CHONDROCYTES IN VITRO", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 296, no. 3, 2002, pages 671 - 676 *
SHIMIZU S. ET AL.: "PREVENTION OF CARTILAGE DESTRUCTION WITH INTRAARTICULAR OSTEOCLASTOGENESIS INHIBITORY FACTOR / STEOPROTEGERIN IN A MURINE MODEL OF OSTEOARTHRITIS", ARTHRITIS RHEUM., vol. 56, no. 10, October 2007 (2007-10-01), pages 3358 - 3365 *
TAKAYANAGI H.: "RAKL.Hakotsu Saibo to OA", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 80, no. 8, 25 August 2006 (2006-08-25), pages S802 *

Also Published As

Publication number Publication date
JPWO2008078588A1 (en) 2010-04-22
TW200833841A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP2104674B8 (en) Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008070268A3 (en) Pharmaceutical compositions
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007084424A3 (en) Treatment of substance abuse
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2007121125A3 (en) Hcv inhibitors
EP2142549A4 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2007092469A3 (en) Combination of organic compounds
WO2012033390A3 (en) Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07850700

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551037

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07850700

Country of ref document: EP

Kind code of ref document: A1